China Medtech: Summer 2025 Executive Briefing

The summer of 2025 marked a pivotal period for China’s medtech sector, defined by a sharp escalation in geopolitical trade measures and a powerful, policy-driven push for domestic manufacturing. While a new EU-China procurement standoff creates immediate market access hurdles for importers, a resilient funding environment and a series of landmark domestic innovations signal the growing strength and sophistication of China’s local ecosystem.

 Key Developments at a Glance:

Policy & Regulatory: Geopolitical Tensions Force a Strategic Shift

• • On July 6, China retaliated against EU trade measures, banning EU-based firms from government tenders for high-value medical devices (e.g., MRI machines) valued over ¥45 million.
  • A critical exemption was made for products manufactured in China by EU-invested firms, creating a powerful incentive for foreign companies to localize production to maintain market access.
  • Domestically, the NMPA proposed longer, more predictable grace periods (2-3 years) for devices up-classified to a higher risk category, aiming to reduce compliance shocks for manufacturers.

Manufacturing & Logistics: “In China, for China” Becomes an Imperative

• • Global giants like Siemens Healthineers are doubling down on localization, with many high-end systems already produced on the mainland, mitigating the impact of the new procurement ban.
  • Germany’s Evonik opened its largest medical device application center in Shanghai, bolstering the domestic supply chain for advanced bioresorbable components.
  • The broader life sciences supply chain was fortified by over $48 billion in pharmaceutical investments in H1 2025, surpassing the total for all of 2024.

Clinical & Patients: Innovative Access Models Mature

• • The Hainan Boao Lecheng Pilot Zone has now introduced 485 advanced overseas medical products, treating over 130,000 patients.
  • In a landmark move, global insurer AXA partnered with the Hainan zone to develop commercial insurance plans covering these advanced therapies, signaling a new phase of commercial viability.
  • New clinical trials were registered for cutting-edge domestic technologies, including intravascular shockwave systems and noninvasive deep brain stimulation devices.

Innovation & IP: Domestic Champions Go Global

• • The NMPA granted approval to China’s first miniature spinal surgical robot, the “Intelligent SpinePecker” fast-tracked via the innovative device pathway.
  • Zai Lab and Novocure received NMPA approval for Optune, the first new treatment for glioblastoma in China in over 15 years.
  • In a sign of growing global ambition, Peijia Medical submitted a 510(k) application to the U.S. FDA for its DCwire® Micro Guidewire, directly targeting the American market.

Funding & Partnerships: Healthcare Bucks the “Venture Winter”

• • While overall venture funding in China fell 34% YoY in Q2, the healthcare sector remained resilient, with biopharma firms raising ~$481 million in July alone.
  • The Hong Kong Stock Exchange cemented its role as the world’s top healthcare fundraising hub, with 10 IPOs raising US$2.1 billion in H1 2025.

Sales & Markets: Procurement Rules Reshape the Playing Field

• • The EU procurement ban immediately disrupted sales channels for imported high-value equipment, creating a protected market for domestic and localized products.
  • H1 financial results from listed firms like Peijia Medical (revenue +17.3%) suggest a gradual market recovery from the 2024 slowdown.
  • China’s medical device exports remain a strong growth engine, with trade value showing a 9.4% compound annual growth rate over the past five years.

The 2025 Medtech Standoff: navigating EU-China Procurement barriers unlocking the In-Country advantage

I. The Geopolitical Chessboard:
A New Era of EU-China Medtech Trade

 The global medical technology landscape has been fundamentally reshaped by a recent and escalating trade dispute between the European Union and China. What began as a move by Brussels to enforce market reciprocity has triggered a calculated and strategically nuanced response from Beijing. This exchange of measures transcends a simple tit-for-tat trade spat; it represents a new phase of industrial policy being conducted through procurement regulations. For European medtech executives, understanding the precise mechanics of these new rules, and, most importantly, the strategic exemptions embedded within them, is critical not only for mitigating risk but for uncovering a significant, time-sensitive opportunity.

The EU’s First Move: Wielding the International Procurement Instrument (IPI)

 The European Commission’s decision to restrict Chinese access to its public procurement market was not an impulsive action but the culmination of years of mounting frustration over perceived market access imbalances. The EU has long contended that while its public procurement market, one of the most open in the world, welcomed Chinese firms, European companies faced significant and recurring barriers in China.¹ Chinese exports of medical devices to the EU, for instance, more than doubled between 2015 and 2023, a period during which European firms reported increasing difficulties accessing the Chinese market.¹

This grievance led the Commission to launch its first-ever investigation under the International Procurement Instrument (IPI) on April 24, 2024.¹ The IPI, a regulation that entered into force in 2022, is designed to provide the EU with leverage to open third-country procurement markets by promoting reciprocity.³ The investigation focused on China’s longstanding industrial policies, such as “Buy China” and the “Made in China 2025” strategy, which explicitly mandate that government entities prioritize domestic goods and aim for domestic market share targets as high as 85% for certain medical device components.³

The findings of the EU’s investigation, published in early 2025, were stark. The Commission concluded there was “clear evidence” of unfair practices, finding that a staggering 87% of public procurement tenders for medical devices in China contained exclusionary and discriminatory measures against EU-made products and suppliers.¹ Despite repeated attempts at dialogue, the Commission stated that China had not offered satisfactory commitments to address these structural barriers.¹

Consequently, the EU moved to apply for the IPI. Effective June 30, 2025, and set for a five-year period, the following measures were imposed on Chinese medical device manufacturers ⁵:

• Chinese-origin companies are barred from bidding on EU public procurement contracts for medical devices with an estimated value exceeding €5 million.¹
• Successful tenderers in these contracts are prohibited from sourcing more than 50% of the total contract value in the form of medical devices originating from China.¹

The EU’s stated objective is to “level the playing field” and incentivize Beijing to grant European firms market access comparable to that which Chinese firms enjoy in the EU.¹ The measures are designed to be proportionate, with exceptions for cases where no alternative suppliers exist, and are framed as consistent with the EU’s international obligations, as it has no binding procurement commitments with China under the WTO framework.¹ 

China’s Calculated Retaliation: A Swift and Precise Countermeasure

 Beijing’s reaction was swift and unequivocal. The Chinese Ministry of Commerce (MOFCOM) and Ministry of Finance (MOF) characterized the EU’s IPI measures as protectionist and unilateral.⁷ In official statements, Chinese authorities asserted that despite their “goodwill and sincerity” expressed through bilateral dialogue, the EU had “insisted on going its own way, taking restrictive measures and building new protectionist barriers”.⁷ As a result, China declared it was “compelled to introduce reciprocal restrictive measures” to safeguard the legitimate rights and interests of its enterprises and maintain a fair competitive environment.⁷

Drawing from official notices published by the MOF and confirmed in state-affiliated media, the Chinese countermeasures took effect on July 6, 2025.²⁰ The restrictions are as follows:

• Enterprises based in the European Union are barred from participating in Chinese government procurement projects for a specified list of medical devices when the project’s budget exceeds 45 million RMB (approximately $6.3 million).⁴
• The affected product categories are primarily high-value capital equipment and implants, including surgical instruments, magnetic resonance imaging (MRI) equipment, blood-based pharmaceutical preparations, orthopedic implant components, and medical laser devices.¹⁵
• For non-EU companies participating in such tenders, the value of any medical devices or components imported from the EU is capped at 50% of the total contract value.⁷

The Critical Exemption: The “In-China-for-China” Loophole

 While Beijing’s response was framed as “reciprocal,” a closer examination reveals a critical and deliberately crafted asymmetry. The most significant feature of China’s countermeasures is a crucial exemption clause. The official notices from the MOF and MOFCOM explicitly state that the procurement ban does not apply to EU-funded businesses operating in China.⁴

This distinction is not a minor detail; it is the central pillar of China’s strategic response. It means that a medical device manufactured in a Chinese facility owned by a European parent company is considered a “domestic” product for the purposes of government procurement and is therefore exempt from the ban. A second, narrower exemption exists for projects where only EU-imported devices can meet the technical procurement requirements, though this is expected to be applied sparingly and subject to administrative discretion.¹⁵

This carefully constructed loophole reveals that the conflict is not merely a trade dispute but an extension of industrial policy conducted through trade instruments. The EU initiated the conflict by using its IPI tool to challenge China’s protectionist industrial strategies. In response, China has not simply erected a retaliatory wall but has engineered a policy that actively serves its own long-term industrial ambitions. A truly reciprocal measure would have been a blanket ban on all EU-origin devices. The inclusion of the exemption for locally operating EU firms is a significant and intentional deviation from that path. This clause aligns perfectly with the overarching goals of national strategies like “Made in China 2025” and successive Five-Year Plans, which aim to domesticate advanced manufacturing, absorb foreign technology, and upgrade China’s industrial base.¹¹ The policy is therefore not designed to push European companies out of the Chinese market, but rather to pull their most valuable assets—their manufacturing capabilities, technology, and R&D—into it. It creates a powerful incentive for European medtech firms to transition from a traditional “export to China” model to a localized “In-China-for-China” strategy.

II. Navigating the Fallout:
Quantifying the Impact on European Medtech

 For European medical technology companies that maintain a purely export-oriented strategy, the new procurement landscape in China presents a multifaceted and severe challenge. The official restrictions on market access are merely the visible tip of an iceberg. Beneath the surface lies a more challenging operating environment characterized by the likely over-zealous enforcement of new and existing rules, the amplification of non-tariff barriers, and disruptive ripple effects across global supply chains.

 Direct Market Access Restrictions: The Tip of the Iceberg

 The most immediate consequence of China’s countermeasures is the direct loss of access to a significant segment of its public procurement market. While a precise valuation of the affected Chinese market segment is difficult to ascertain, its importance to European exporters is undeniable. China is a primary trade partner for the EU medtech industry, with Europe enjoying a positive trade balance in the sector.³³ Major European medtech exporting nations, including Germany, Ireland, the Netherlands, and Switzerland, will feel the impact directly.³³ In 2024, Germany alone exported goods worth €90 billion to China across all sectors, highlighting the scale of the trade relationship.³⁴

The ban on tenders exceeding 45 million RMB for high-value equipment such as MRI systems, orthopedic implants, and advanced surgical instruments effectively closes the door on a lucrative market for many of Europe’s most innovative companies.¹⁵ This direct market foreclosure represents a tangible and immediate revenue risk for any firm reliant on exporting these products from European manufacturing sites. The scale of the EU market now partially closed to Chinese firms offers a sense of the potential stakes; the EU’s medtech public procurement market is valued at approximately €150 billion annually, with tenders over €5 million accounting for roughly 60% of this value, or about €90 billion per year.³⁵ Losing access to a correspondingly significant portion of China’s market will have a material impact on European exporters.

The Unwritten Rules: “Over-Zealous” Enforcement and Non-Tariff Barriers

 Beyond the explicit text of the new regulations, a more profound challenge lies in their likely implementation. China has a well-documented history of utilizing a complex web of non-tariff barriers, opaque administrative hurdles, and selective regulatory enforcement to protect and promote its domestic industries.³⁶ These tactics can range from creating unique and burdensome licensing requirements to leveraging broad national security laws to control data, technology, and intellectual property.³⁷ It is highly probable that the new procurement restrictions will be enforced with a degree of patriotic zeal by provincial and municipal procurement authorities, who are already under pressure to favor local champions.

This new procurement ban must be understood not in isolation, but as an enforcement mechanism for pre-existing industrial policies. Two key policies will be amplified by the new rules:

1. Volume-Based Procurement (VBP): This system, through which the government centralizes the purchasing of medical supplies and drugs to negotiate aggressively lower prices, already places immense margin pressure on foreign brands, which often struggle to compete on price with subsidized domestic rivals.³ The new procurement ban adds another layer of difficulty: imported products are not only at a price disadvantage but are now explicitly disqualified from many high-value tenders, further strengthening the negotiating position of domestic suppliers.
2. “Made in China 2025”: The procurement ban provides local officials with a clear legal and political mandate to advance the goals of this overarching industrial strategy.¹¹ The policy’s explicit target of achieving 80% domestic market share for core medical device components by 2025 creates a powerful incentive for procurement decision-makers to reject imported products.³⁰ The new rules effectively give these officials the legal cover to do so, transforming a strategic goal into an operational reality.

Ripple Effects Across the Global Value Chain

 The impact of China’s countermeasures extends far beyond the EU’s borders, creating significant collateral damage for global medtech firms. The rule stipulating that non-EU companies cannot source more than 50% of a contract’s value from the EU introduces a major compliance burden and supply chain challenge.⁷

An American, Japanese, or Swiss medical device company that relies on critical, high-value components from Germany, Ireland, or France for devices assembled in the US or Southeast Asia will now face a difficult choice. To compete for large tenders in China, they must either conduct a costly and complex audit of their entire bill of materials to ensure compliance with the 50% cap or undertake a strategic and potentially disruptive re-sourcing of key components away from their trusted European suppliers.⁵ This forces a supply chain re-evaluation upon a wide range of global players who may have had no direct involvement in the initial EU-China dispute.

Simultaneously, the dynamics of the European market itself are set to shift. With Chinese medtech firms now facing restrictions in the €90 billion EU public procurement market, they are likely to redirect their competitive efforts. This could lead to increased price pressure in the EU’s private healthcare markets or in other global regions where they will seek to offload capacity. At the same time, American and other international firms may view the EU’s restrictions on Chinese suppliers as a strategic opportunity to capture market share within Europe, intensifying competition for all players.³

The architecture of China’s countermeasures appears deliberately designed to create a bifurcated risk environment. For companies committed to a pure export model, the political, regulatory, and commercial risks of serving the Chinese market have been amplified dramatically. The official ban is the starting point, but the unwritten rules of zealous local enforcement and the weaponization of existing industrial policies like VBP make the de facto barriers even higher than the de jure ones. In contrast, for companies willing to localize their operations, these escalating risks are not only mitigated but are replaced by a suite of powerful incentives. The Chinese government is thus actively managing the risk landscape to channel foreign corporate behavior. It is systematically making the status quo—exporting from abroad—commercially hazardous while making the desired future—localizing production within China—an attractive, de-risked proposition.

III. The Strategic Pivot:
Turning Crisis into Opportunity with an “In-China-for-China” Strategy

 While the escalating trade friction presents formidable challenges for unprepared European medtech firms, it simultaneously unveils a clear strategic pathway for growth and long-term success in the Chinese market. The very structure of China’s retaliatory measures contains the solution. Localization of manufacturing is no longer merely a cost-saving tactic or a “nice-to-have” element of a global footprint; it has become a fundamental strategic imperative for market access, risk mitigation, and competitive advantage in China.

The ‘Golden Ticket’: How In-Country Manufacturing Bypasses Procurement Barriers

 The most direct and powerful benefit of establishing a manufacturing presence in China is the ability to completely bypass the new procurement restrictions. As explicitly stated in the official government notices, a medical device produced within China—even in a facility that is wholly owned by a foreign parent company—is classified as a “domestic” product.⁴ This “golden ticket” transforms a company from a target of the protectionist measures into a participant, and potential beneficiary, of the domestic industrial ecosystem.

Simply avoiding the ban is only the first step. By achieving “domestic” status, products from foreign-invested enterprises (FIEs) may become eligible for preferential treatment in government tenders. A draft notice circulated by China’s Ministry of Finance in late 2024 proposed granting a 20% price review discount to domestic products compared to non-domestic products in government procurement bids.¹¹ While this remains a draft, it provides a clear signal of the policy direction and the tangible financial advantages that localization can confer. This shifts the competitive dynamic from being penalized for being foreign to being rewarded for being local.

Beyond Circumvention: The Compounding Benefits of Localization

 The strategic rationale for localization extends far beyond circumventing the immediate procurement crisis. The Chinese government has constructed a holistic and integrated policy ecosystem designed to attract and support advanced manufacturing. This ecosystem provides a powerful set of compounding benefits across regulatory, financial, and operational domains.

Regulatory Tailwinds

• Expedited Approvals (Order 104): Recognizing the need to facilitate localization, China’s National Medical Products Administration (NMPA) has created an accelerated registration pathway for foreign companies wishing to manufacture their already-approved imported devices in China. Known as Order 104, this policy allows for the reuse of up to 80% of the original import application documents, dramatically reducing bureaucracy and speeding up time-to-market for localized products.³⁰
• Marketing Authorization Holder (MAH) System: Perhaps the most transformative regulatory reform, the MAH system decouples the marketing authorization (the product license) from the manufacturing license. This allows a foreign entity to hold the product registration and be fully responsible for the product’s quality and lifecycle, while outsourcing the physical production to a qualified local contract manufacturer (with limited exceptions). This model provides enormous flexibility, significantly lowers capital expenditure, and is an ideal pathway for companies seeking an asset-light entry into local production.³¹

Economic and Financial Incentives

• Access to Government Funding: Localized operations, particularly those involving R&D and advanced technology, can become eligible to tap into a growing network of government-backed venture capital and industrial investment funds. The city of Shanghai, for example, has established an RMB 89 billion industrial fund with a specific allocation of RMB 21.5 billion for high-end medical devices and innovative drugs.⁴⁴
• Tax Benefits and Subsidies: China offers a suite of powerful financial incentives to promote high-tech manufacturing and innovation. A key incentive is the R&D “super deduction” policy, which allows qualified manufacturing firms to deduct 200% of their eligible R&D expenditures from their taxable income, substantially lowering their corporate tax burden.⁴⁵ Additionally, local governments frequently offer their own packages of grants, subsidies, and other financial support to attract strategic investments.³²

Operational and Supply Chain Advantages

• Cost Efficiency and Proximity: Manufacturing in China provides direct access to a deep and efficient ecosystem of raw material suppliers, component manufacturers, and skilled labor, which can significantly reduce overall production costs.⁴⁷
• Supply Chain Resilience: An in-country manufacturing footprint insulates a company from the volatility of global shipping, cross-border tariffs, and geopolitical disruptions. Proximity to the vast Chinese end-market shortens product lead times, reduces logistics costs, and enables greater responsiveness to shifting customer demands.

Conclusion. A Blueprint for Action:
Recommendations for European Medtech Leadership

 The convergence of these policies demonstrates that China’s localization push is a deeply integrated, whole-of-government strategy. The procurement ban from the MOF creates the “stick,” while the regulatory fast-tracks from the NMPA, the financial incentives from tax authorities, and the investment from local governments provide a powerful array of “carrots.” For European medtech leaders, recognizing this interconnected policy ecosystem is the key to understanding the full magnitude of the strategic opportunity at hand.

The new reality of EU-China medtech trade demands more than a reactive, wait-and-see approach. It calls for a decisive strategic pivot. For European medtech leadership, the current challenges should be viewed as a catalyst to reconfigure their China strategy for the next decade.

• The first step is a rigorous and unsentimental evaluation of the company’s entire product portfolio through the new lens of China’s market realities. This assessment should move beyond simple revenue figures to analyze vulnerability and opportunity.
• Once priority products have been identified, the next step is to determine the most appropriate market entry and manufacturing model. This decision should be a deliberate strategic choice based on the company’s unique circumstances.
• With a clear strategy and chosen model, the focus must shift to disciplined, on-the-ground execution. Navigating the complexities of the Chinese business and regulatory environment requires meticulous planning and expert guidance.

The process of establishing a legal entity, securing NMPA approvals, qualifying for tax incentives, and complying with local labor and environmental laws is highly complex. Engaging experienced, on-the-ground advisors who possess deep expertise in China industrial localization is crucial for ensuring a smooth, compliant, and efficient implementation, minimizing unforeseen delays and costly missteps, and ultimately maximizing the return on this critical strategic investment.

References

1. EU Curbs Chinese Role in Medical Devices Procurement | Mirage …, accessed July 7, 2025, https://www.miragenews.com/eu-curbs-chinese-role-in-medical-devices-1481732/
2. Commission restricts Chinese participation in medical devices procurement, accessed July 7, 2025, https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1569
3. Medical devices: new EU restrictions will badly hurt Chinese manufacturers – Credendo, accessed July 7, 2025, https://credendo.com/en/knowledge-hub/medical-devices-new-eu-restrictions-will-badly-hurt-chinese-manufacturers
4. China Imposes Reciprocal Restrictions on EU Medical Devices – Morningstar, accessed July 7, 2025, https://www.morningstar.com/news/dow-jones/202507061037/china-imposes-reciprocal-restrictions-on-eu-medical-devices
5. EUROPE – European Commission Excludes Chinese Medical Device Manufacturers from EU Public Procurement Contracts – King & Spalding, accessed July 7, 2025, https://www.kslaw.com/news-and-insights/europe-european-commission-excludes-chinese-medical-device-manufacturers-from-eu-public-procurement-contracts
6. EU Votes to Curb China’s Access to Medical Device Procurement – Insurance Journal, accessed July 7, 2025, https://www.insurancejournal.com/news/international/2025/06/03/826054.htm
7. China strikes back at EU with procurement ban on medical devices | Caliber.Az, accessed July 7, 2025, https://caliber.az/en/post/china-strikes-back-at-eu-with-procurement-ban-on-medical-devices
8. European Union Votes to Curb China’s Access to Medical Device Market – Knobbe Martens, accessed July 7, 2025, https://www.knobbe.com/blog/european-union-votes-to-curb-chinas-access-to-medical-device-market/
9. SWD%282025%292%20final.ENG.xhtml.1_EN_autre_document_travail_service_part1_v3.docx – EUR-Lex, accessed July 7, 2025, https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52025SC0002
10. EU restrictions to hit Chinese MedTech manufacturers – Medical Buyer, accessed July 7, 2025, https://medicalbuyer.co.in/eu-restrictions-to-hit-chinese-medtech-manufacturers/
11. Access2Markets Barrier: Medical Devices (Buy China policy) – European Commission’s trade, accessed July 7, 2025, https://trade.ec.europa.eu/access-to-markets/en/barriers/details?barrier_id=14587
12. EU green lights restriction to EU public procurement for medical devices and companies from China – MedTech Europe, accessed July 7, 2025, https://www.medtecheurope.org/news-and-events/news/eu-green-lights-restriction-to-eu-public-procurement-for-medical-devices-and-companies-from-china/
13. EU excludes Chinese companies from procurement of medical devices over €5 million, accessed July 7, 2025, https://www.euractiv.com/section/health-consumers/news/eu-excludes-chinese-companies-from-procurement-of-medical-devices-over-e5-million/
14. China voices opposition to EU’s limits on medical device procurement – CGTN, accessed July 7, 2025, https://news.cgtn.com/news/2025-06-24/China-voices-opposition-to-EU-s-limits-on-medical-device-procurement-1EsF9zi3O8w/p.html
15. Steps taken against EU medical device curbs – Chinadaily.com.cn, accessed July 7, 2025, http://www.chinadaily.com.cn/a/202507/07/WS686b0acfa31000e9a573a6e4.html
16. China retaliates to EU ban with import restrictions on medical devices – The Economic Times, accessed July 7, 2025, https://m.economictimes.com/news/international/world-news/china-restricts-eu-imports-of-medical-devices/articleshow/122277691.cms
17. Steps taken against EU medical device curbs – Chinadaily.com.cn, accessed July 7, 2025, https://www.chinadaily.com.cn/a/202507/07/WS686b0acfa31000e9a573a6e4.html
18. China announces reciprocal measures on medical device imports from EU in government procurement – Global Times, accessed July 7, 2025, https://www.globaltimes.cn/page/202507/1337722.shtml
19. China takes countermeasures against EU medical device curbs, accessed July 7, 2025, https://www.chinadailyhk.com/article/615323
20. 突发！财政部、商务部发声，今起执行！ – 证券时报, accessed July 7, 2025, http://stcn.com/article/detail/2419512.html
21. 商务部新闻发言人就在政府采购活动中对自欧盟进口的医疗器械采取 …, accessed July 7, 2025, http://www.mofcom.gov.cn/syxwfb/art/2025/art_09231d3f57b8471caf3d43d6052aa60e.html
22. China retaliates to EU ban with import restrictions on medical devices – The Japan Times, accessed July 7, 2025, https://www.japantimes.co.jp/news/2025/07/06/world/china-eu-import-restrictions/
23. 财政部：在政府采购活动中对自欧盟进口的医疗器械采取相关措施, accessed July 7, 2025, https://www.yicai.com/news/102707675.html
24. China retaliates to EU ban with import restrictions on medical devices | 1450 AM 99.7 FM WHTC | Holland, accessed July 7, 2025, https://whtc.com/2025/07/06/china-retaliates-to-eu-ban-with-import-restrictions-on-medical-devices/
25. China retaliates against EU ban with import restrictions on medical devices, accessed July 7, 2025, https://www.straitstimes.com/world/china-retaliates-to-eu-ban-with-import-restrictions-on-medical-devices
26. China introduces Reciprocal Measures for EU purchases of Medical Equipment, accessed July 7, 2025, https://sarajevotimes.com/china-introduces-reciprocal-measures-for-eu-purchases-of-medical-equipment/
27. China targets EU medical devices in new import restrictions – Amwal Al Ghad, accessed July 7, 2025, https://en.amwalalghad.com/china-targets-eu-medical-devices-in-new-import-restrictions/
28. China-EU trade row: Beijing bans European firms from major medical bids; says Brussels must end ‘discriminatory’ practices, accessed July 7, 2025, https://timesofindia.indiatimes.com/business/international-business/china-eu-trade-row-beijing-bans-european-firms-from-major-medical-bids-says-brussels-must-end-discriminatory-practices/articleshow/122278665.cms
29. Made in China 2025 – Institute for Security & Development Policy, accessed July 7, 2025, https://www.isdp.eu/wp-content/uploads/2018/06/Made-in-China-Backgrounder.pdf
30. Going Local: Strategic Considerations for Medtech Manufacturers in China – L.E.K. Consulting, accessed July 7, 2025, https://www.lek.com/sites/default/files/PDFs/china-localization.pdf
31. Medical Device Made-in-China Policy: A Comprehensive Review and Implementation (I), accessed July 7, 2025, https://chinameddevice.com/made-in-china-policy/
32. Investigating state support for China’s medical technology companies, accessed July 7, 2025, https://merics.org/sites/default/files/2023-11/MERICS_Report_MedTech%20State%20Support_November%202023_final.pdf
33. Trade – MedTech Europe – The European Medical Technology in Figures, accessed July 7, 2025, https://www.medtecheurope.org/datahub/trade/
34. China-EU – international trade in goods statistics – European Commission, accessed July 7, 2025, https://ec.europa.eu/eurostat/statistics-explained/index.php/China-EU_-_international_trade_in_goods_statistics
35. EU bars Chinese firms from most medical device tenders | 1330 …, accessed July 7, 2025, https://whbl.com/2025/06/20/eu-bars-chinese-firms-from-most-medical-device-tenders/
36. Protectionism in China: Forms, Purpose & Outlook – Intrepid Sourcing, accessed July 7, 2025, https://intrepidsourcing.com/trade-wiki/protectionism-forms-purpose-outlook/
37. China’s technology protectionism and its non-negotiable rationales – European Centre for International Political Economy, accessed July 7, 2025, https://ecipe.org/wp-content/uploads/2017/06/DTE_China_TWP_REVIEWED.pdf
38. China’s Recent Trade Measures and Countermeasures: Issues for Congress, accessed July 7, 2025, https://www.congress.gov/crs-product/R46915
39. China’s Shifting Regulatory Landscape for Medical Devices: A 2025 Update, accessed July 7, 2025, https://www.pacificbridgemedical.com/uncategorized/chinas-shifting-regulatory-landscape-for-medical-devices-a-2025-update/
40. The New Frontier in Medtech: Navigating China-EU Trade Tensions for Investment Gains, accessed July 7, 2025, https://www.ainvest.com/news/frontier-medtech-navigating-china-eu-trade-tensions-investment-gains-2507/
41. china encourages local manufacturing of foreign medical devices – Asia Actual, accessed July 7, 2025, https://asiaactual.com/blog/china-encourages-local-manufacturing-of-foreign-medical-devices/
42. Empowering the Medtech Industry with Effective Regulatory Incentives – Ropes & Gray LLP, accessed July 7, 2025, https://www.ropesgray.com/-/media/files/articles/2022/09/20220906_medtech_whitepaper_english.pdf
43. Going Local: Strategic Considerations for Medtech Manufacturers in China | L.E.K. Consulting, accessed July 7, 2025, https://www.lek.com/insights/hea/cn/ei/going-local-strategic-considerations-medtech-manufacturers-china
44. China’s medical device investment: Key trends for the future – Daxue Consulting, accessed July 7, 2025, https://daxueconsulting.com/china-medical-device-investment/
45. China’s rising dominance in Global MedTech ecosystem, accessed July 7, 2025, https://www.praxisga.com/insights/healthcare-and-lifesciences/china-rising-dominance
46. China’s Medical Device Market A Land Of Opportunity And Challenges, accessed July 7, 2025, https://www.meddeviceonline.com/doc/china-s-medical-device-market-a-land-of-opportunity-and-challenges-0001
47. 6 Advantages of Medical Device Manufacturing in China Post Covid-19, accessed July 7, 2025, https://quasarmedical.com/education/medical-device-manufacturing-china/
48. “Made in China policy” of medical device, accessed July 7, 2025, https://www.easychinapprov.com/why-choose-china-for-contract-manufacturing-of-medical-devices
49. Medical device manufacturing in China: Trends and developments – Daxue Consulting, accessed July 7, 2025, https://daxueconsulting.com/medical-device-manufacturing-in-china/
50. Eight Reasons Why Foreign Companies Fail in China – Localization Services, accessed July 7, 2025, https://www.getblend.com/blog/why-foreign-companies-fail-china/